Board of Directors

Kyran McLaughlin, Chairman

Kyran McLaughlin was appointed a Director of Elan in January 1998 and was appointed Chairman of Elan in January 2005. He is Deputy Chairman at Davy Stockbrokers, Ireland’s largest stockbroker firm. He is also a Director of Ryanair Holdings, plc and is a Director of a number of private companies.

Back to top Kelly Martin, Chief Executive Officer

G. Kelly Martin was appointed a Director of Elan in February 2003, following his appointment as President and Chief Executive Officer. He was formerly a member of the executive management committee of Merrill Lynch & Co., Inc., where he spent more than 20 years in a broad array of operating responsibilities on a global basis.

Back to top Shane Cooke, Executive Vice President, Chief Financial Officer and Head of Elan Drug Technologies

Shane Cooke was appointed a Director of Elan in May 2005, having joined the company as Executive Vice President and Chief Financial Officer in July 2001. He was appointed head of Elan Drug Technologies in May 2007 Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that held a number of senior positions in finance in the banking and aviation industries. Mr. Cooke is a chartered accountant and a graduate of University College Dublin.

Back to top Vaughn Bryson, Director

Vaughn Bryson was appointed a Director of Elan in July 2009 and has over 40 years of experience as an executive, a director and advisor in the healthcare industry. He spent 32 years with Eli Lilly and Co. completing his career there as President and Chief Executive Officer. From April 1994 to December 1996, Mr. Bryson was Vice Chairman of Vector Securities International, a healthcare focused investment banking firm. Mr. Bryson was President of Life Science Advisors, LLC, a healthcare consulting company from 1995 to 2004. He has served on the board of directors of many public and private companies including Eli Lilly & Co., Amylin Pharmaceuticals Inc., Quintiles Transnational and Chiron Corporation. Mr. Bryson received a B.S. in Pharmacy from the University of North Carolina and completed the Sloan Program at the Stanford University Graduate School of Business Administration.

Back to top Lars Ekman, Director

Lars Ekman was appointed a Director of Elan in May 2005. He transitioned from his role as Elan's President of Research and Development in December 2007 to serve solely as a Director. He joined Elan as Executive Vice President and President, Global R&D in 2001. Prior to joining Elan, he was Executive Vice President, R&D, at Schwarz Pharma AG since 1997.From 1984 to 1997, Dr. Ekman was employed in a variety of senior scientific and clinical functions at Pharmacia (now Pfizer). Dr. Ekman is a board certified surgeon with a PhD in experimental biology and has held several clinical and academic positions in both the United States and Europe. He obtained his PhD and MD from the University of Gothenburg, Sweden. He serves as an Executive-in-Residence to Sofinnova Ventures and as an advisor to Warburg Pincus. He is a Director of Amarin Corporation, plc. ARYx Therapeutics, Inc., Cebix Incorporated and InterMune, Inc.

Back to top Jonas Frick, Director

Jonas Frick was appointed a Director of Elan in September 2007. He is the former Chief Executive Officer of Scandinavian Life Science Ventures. He was the CEO and President of Medivir AB, and served in senior executive positions in Pharmacia's international businesses in the CNS and Autoimmune areas across Italy, Sweden and Japan. He is a founding member of the Swedish Biotechnology Industry Organization and is the owner of Acacia Partners and is Chairman of Frick Management AB.

Back to top Gary Kennedy, Director

Gary Kennedy was appointed a Director of Elan in May 2005. From May 1997 to December 2005, he was Group Director, Finance & Enterprise Technology, at Allied Irish Banks, plc (AIB) and a member of the main Board of AIB and was also on the Board of M&T, AIB's associate in the United States. Prior to that, Mr. Kennedy was Group Vice President at Nortel Networks Europe after starting his management career at Deloitte & Touche. He served on the Board of the Industrial Development Authority of Ireland for 10 years until he retired in December 2005. He is a Director of Greencore Group, plc and a number of private companies. Mr. Kennedy is a chartered accountant.

Back to top Patrick Kennedy, Director

Patrick Kennedy was appointed a Director of Elan in May 2008. He is Chief Executive of Paddy Power plc, an international betting and gaming group listed on both the London and Irish Stock Exchanges. Mr. Kennedy was previously Chief Financial Officer of Greencore Group plc and prior to that worked with McKinsey & Company and KPMG. Mr. Kennedy is a graduate of University College Dublin and a Fellow of the Institute of Chartered Accountants in Ireland.

Back to top Giles Kerr, Director

Giles Kerr was appointed a Director of Elan in September 2007. He is currently the Director of Finance with the University of Oxford, England, and a Fellow of Keble College. He is also a Director and Chairman of the Audit Committee of Victrex plc and a Director of BTG plc, Isis Innovation Ltd and a number of private companies. Previously, he was the Group Finance Director and Chief Financial Officer of Amersham plc, and prior to that, he was a partner with Arthur Andersen in the United Kingdom.

Back to top Kieran McGowan, Director

Kieran McGowan was appointed a Director of Elan in December 1998. From 1990 until his retirement in December 1998, he was chief executive of the Industrial Development Authority of Ireland. He is Chairman of CRH, plc. He is also a Director of United Drug, plc, and of a number of private companies.

Back to top Donal O'Connor, Director

Donal O'Connor was appointed a Director of Elan in May 2008. He was Senior Partner of PricewaterhouseCoopers in Ireland from 1995 until 2007 and was a member of the PricewaterhouseCoopers Global Board and is a former Chairman of the Eurofirms Board. He is Executive Chairman of Anglo Irish Bank, plc and a Director of Readymix, plc and the Administrator of Icarom plc. He is a graduate of University College Dublin and a Fellow of the Institute of Chartered Accountants in Ireland.

Back to top Richard Pilnik, Director

Richard Pilnik was appointed a Director of Elan in July 2009 and brings extensive industry experience to Elan, having served in several leadership positions during his 25-year career at Eli Lilly and Company. Most recently at Eli Lilly, Mr. Pilnik served as Group Vice President and Chief Marketing Officer, where he was directly responsible for commercial strategy, market research and medical marketing. Prior to that, Mr. Pilnik served as President of Eli Lilly Europe, Middle East, Africa and the Commonwealth of Independent States (CIS), a regional organization of former Soviet Republics, where he oversaw 50 countries and positioned Eli Lilly as the fastest growing pharmaceutical company in the region. Mr. Pilnik also held several marketing and sales management positions in the United States, Europe and Latin America during his tenure at Eli Lilly. Currently, Mr. Pilnik serves as President of Innovex, the commercial group of Quintiles Transnational Corp., which is a global pioneer in pharmaceutical services. Mr. Pilnik holds a B.A. from Duke University and an M.B.A. from the Kellogg School of Management at Northwestern University.

Back to top William Rohn, Director

William R. Rohn was appointed a Director of Elan in May 2006. He is currently a Director of Cebix, Inc., Cerus Corp. and Metabasis Therapeutics, Inc. Previously, he was Chief Operating Officer of Biogen Idec until January 2005 and prior thereto President and Chief Operating Officer of Idec Pharmaceutical Corporation from 1993.

Back to top Jack Schuler, Director

Jack Schuler was appointed Director of Elan in July 2009 and has nearly 40 years of experience as an executive, a director and investor in the healthcare industry. He is currently a partner in Crabtree Partners, LLC, a private investment firm located in Lake Forest, Illinois and a director of Medtronic Inc., Quidel Corporate and Stericycle Inc. He spent 17 years at Abbott Laboratories, where he rose to the position of President and Chief Operating Officer. Mr. Schuler left his executive role at Abbott Laboratories to help launch and grow several healthcare companies, including Ventana Medical Systems and Stericycle. Mr. Schuler has also served as a member of the board of directors of ICOS Corporation, Chiron Corporation, Amgen Inc., and Abbott Laboratories. Mr. Schuler holds a B.S. in Mechanical Engineering from Tufts University and an M.B.A. from Stanford University Graduate School of Business.

Back to top Dennis Selkoe, Director

Dennis Selkoe was originally appointed a director of Elan in July 1996, following our acquisition of Athena Neurosciences, where he served as a director since July 1995. Dr. Selkoe was a founder of Athena. Dr. Selkoe, a neurologist, is a professor of neurology and neuroscience at Harvard Medical School. He also serves as co-director of the Center for Neurologic Diseases at The Brigham and Women’s Hospital. Dr. Selkoe retired as a director of Elan in July 2009 and was reappointed in August 2009.

Back to top